ID
45794
Beschrijving
Principal Investigator: David Hafler, Yale School of Medicine, New Haven, CT, USA MeSH: Glioblastoma,Programmed Cell Death 1 Receptor https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001079 PD-1 is an important immune checkpoint inhibitor that shows great promise in the clinic, particularly for melanoma and lung cancers. Since PD-1 is also expressed on infiltrating CD4+ Treg and Teffector cells in glioblastoma, we sought to better understand the role of PD-1 on these infiltrating CD4+ Treg and Teffector cells. To this end, we performed functional and transcriptional profiling using CD4+ Treg and Teffector cells isolated from healthy donors and glioblastoma patients (from both tumors and blood).
Link
Trefwoorden
Versies (1)
- 23.06.23 23.06.23 - Chiara Middel
Houder van rechten
David Hafler, Yale School of Medicine, New Haven, CT, USA
Geüploaded op
23. Juni 2023
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs001079 PD-1+ and PD-1- CD4+ Teff and Treg cells in Glioblastoma and Health
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
- Subject ID, sample ID, and sample use of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
- Sample ID, MGMT methylation, sorted as PD1pos or PD1- or total, sample obtained from tumor or blood, and tumor stage of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
- Subject ID, sample ID, and sample use of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
- Sample ID, MGMT methylation, sorted as PD1pos or PD1- or total, sample obtained from tumor or blood, and tumor stage of participants with or without glioblastoma and involved in the "Transcriptional Profiling of PD-1+ and PD-1- Teff and Treg Cells in Glioblastoma and Health" project.
C0680251 (UMLS CUI [1,2])
C0229664 (UMLS CUI [1,2])
C0370003 (UMLS CUI [1,3])
C1516698 (UMLS CUI [1,4])
C0006118 (UMLS CUI [1,5])
C0543467 (UMLS CUI [1,6])
C1292533 (UMLS CUI [2,1])
C0229664 (UMLS CUI [2,2])
C0370003 (UMLS CUI [2,3])
C1516698 (UMLS CUI [2,4])
C1708335 (UMLS CUI [2,5])